2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.
Carlo Visco, MD, associate professor, Department of Medicine, Section of Hematology, University of Verona, Verona, Italy, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma (MCL).
As demonstrated in past studies, younger patients with MCL should receive higher doses of cytarabine during induction therapy to obtain optimal results, says Visco. Notably, cytarabine-based regimens have become a standard in the space.
Conversely, elderly patients cannot tolerate high doses of this agent, Visco explains.
As such, future research efforts should aim to identify additional first-line treatment regimens for older patients with MCL, Visco concludes.